Medtronic PLC $MDT Position Increased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. grew its position in Medtronic PLC (NYSE:MDT) by 6.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,057,958 shares of the medical technology company’s stock after buying an additional 68,298 shares during the quarter. Nomura Asset Management Co. Ltd. owned approximately 0.08% of Medtronic worth $92,222,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MDT. 1248 Management LLC acquired a new position in Medtronic in the 1st quarter worth approximately $26,000. Twin Tree Management LP purchased a new stake in shares of Medtronic in the first quarter valued at $29,000. Activest Wealth Management boosted its position in shares of Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares during the period. Investment Management Corp VA ADV grew its holdings in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after buying an additional 238 shares in the last quarter. Finally, GFG Capital LLC purchased a new position in shares of Medtronic during the second quarter valued at $36,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research reports. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Friday. Royal Bank Of Canada restated an “outperform” rating and set a $111.00 price target on shares of Medtronic in a report on Friday, October 10th. The Goldman Sachs Group dropped their price objective on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research note on Wednesday, October 1st. Daiwa Capital Markets lifted their target price on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Robert W. Baird upped their price target on shares of Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $103.06.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was purchased at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. 0.26% of the stock is currently owned by company insiders.

Medtronic Stock Down 0.2%

Medtronic stock opened at $95.92 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $99.37. The firm’s fifty day simple moving average is $94.43 and its 200-day simple moving average is $90.43. The company has a market capitalization of $123.04 billion, a P/E ratio of 26.42, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same period in the prior year, the business posted $1.23 earnings per share. The business’s quarterly revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.